Design Therapeutics Reports RESTORE-FA Progress and Advances GeneTAC® Pipeline
CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CARLSBAD, Calif., Aug. 3, 2026 Design Therapeutics, Inc. reported second-quarter 2026 financial results while providing key clinical updates across...
